Regarding new therapies, c-mAbs might constitute specific tools for detecting and targeting Bcl-xL as a strategic protein target in brain injuries relevant to stroke or neurodegenerative diseases. This evidence concerns the gene BCL2L1 and neurodegenerative disease.